Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans~ Underscores Strategic Execution Plans, Regulatory Risk Mitigation Efforts, Pipeline Prioritization, and the Commercial Potential of PF614 ~
Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology~ Phase 1 Data Published in Journal of Opioid Management Validates First-in-Class Overdose-Limiting Opioid Technology of PF614-MPAR ~
Rapid Dose Therapeutics (CSE: DOSE) (OTCQB: RDTCF) Advances QuickStrip™ Research Backed by NFL-Supported Clinical Evaluation – More Stocks InsideRapid Dose Therapeutics (CSE: DOSE; OTCQB: RDTCF ), a biotechnology and drug delivery innovation company, is accelerating clinical validation of its proprietary QuickStrip™ oral thin film delivery system through expanded cannabinoid research and a high-profile study supported by the National Football League (NFL) .
Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder ValueReview Includes Strategic Partnerships, Licensing and Other Corporate Transactions Focused on Advancing TAAPTM and MPAR® Platforms
Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events~ Company leadership to highlight TAAP and MPAR programs, discuss innovation in pain therapeutics and present on commercial excellence ~
Ensysce Biosciences Expands Global Opioid Patent Portfolio~ TAAP™ and MPAR® technologies extended across opioid products to advance safer pain treatment ~
Ensysce Biosciences Issues Annual Shareholder LetterPF614-301 Phase 3 Trial Enrollment Underway, Advancing Toward Market Launch
